Status:
COMPLETED
Exploratory Study of Pagoclone in Men With Premature Ejaculation.
Lead Sponsor:
Endo Pharmaceuticals
Conditions:
Premature Ejaculation
Eligibility:
MALE
18-55 years
Phase:
PHASE2
Brief Summary
The purpose of this study is to evaluate pagoclone in the treatment of premature ejaculation.
Detailed Description
The primary objective of this study is to evaluate the effect of 3 dose levels of pagoclone (0.15 mg, 0.30 mg, and 0.60 mg) versus placebo on intravaginal ejaculation latency time (IELT) male patients...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- A male regularly experiencing premature ejaculation
- 18 to 55 yrs old
- In a Stable relationship with one woman for at least 6 months
Exclusion
Key Trial Info
Start Date :
July 1 2006
Trial Type :
INTERVENTIONAL
End Date :
October 1 2006
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT00370981
Start Date
July 1 2006
End Date
October 1 2006
Last Update
December 27 2013
Active Locations (16)
Enter a location and click search to find clinical trials sorted by distance.
1
Urology Centers of Alabama, PC
Homewood, Alabama, United States, 35209
2
SD Uro-Research
San Diego, California, United States, 92103
3
Urology Research Options
Aurora, Colorado, United States, 80012
4
Urology Associates, PC
Denver, Colorado, United States, 80210